
OXBOF
Healthcare · Diagnostics & Research · $40.3M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jan 27, 2021 | After the close | 0.00 | -0.02 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jan 22, 2020 | After the close | 0.00 | -0.01 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| May 27, 2019 | After the close | 0.00 | -0.01 | — |
| Mar 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Dec 11, 2018 | Before the open | 0.00 | -0.01 | — |
| Sep 30, 2018 | Time not confirmed | 0.00 | -0.01 | — |
| May 21, 2018 | After the close | 0.00 | -0.01 | — |
| Jan 29, 2018 | After the close | 0.00 | -0.01 | — |
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy.…